AUVELITY Drug Patent Profile

Which patents cover Auvelity, and what generic alternatives are available?

Auvelity is a drug marketed by Axsome and is included in one NDA. There are one hundred and twenty-five patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-eight patent family members in thirty-four countries.

The generic ingredient in AUVELITY is bupropion hydrochloride; dextromethorphan hydrobromide. There are thirty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bupropion hydrochloride; dextromethorphan hydrobromide profile page.

DrugPatentWatch^® Generic Entry Outlook for Auvelity

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 5, 2034. This may change due to patent challenges or generic licensing.

There have been nine patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AUVELITY

International Patents:	238
US Patents:	125
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Drug Prices:	Drug price information for AUVELITY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AUVELITY
What excipients (inactive ingredients) are in AUVELITY?	AUVELITY excipients list
DailyMed Link:	AUVELITY at DailyMed

See drug prices for AUVELITY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AUVELITY

Constraining patent/regulatory exclusivity:

11,191,739

NDA:

215430

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AUVELITY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Virginia Commonwealth University	Phase 1/Phase 2
National Institute on Drug Abuse (NIDA)	Phase 1/Phase 2

See all AUVELITY clinical trials

Pharmacology for AUVELITY

Drug Class	Aminoketone Sigma-1 Agonist Uncompetitive N-methyl-D-aspartate Receptor Antagonist
Mechanism of Action	Dopamine Uptake Inhibitors Norepinephrine Uptake Inhibitors Sigma-1 Receptor Agonists Uncompetitive NMDA Receptor Antagonists
Physiological Effect	Increased Dopamine Activity Increased Norepinephrine Activity

Paragraph IV (Patent) Challenges for AUVELITY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AUVELITY	Extended-release Tablet	bupropion hydrochloride; dextromethorphan hydrobromide	45 mg/105 mg	215430	1	2022-12-22

US Patents and Regulatory Information for AUVELITY

AUVELITY is protected by one hundred and twenty-five US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 11,191,739.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-001	Aug 18, 2022		RX	Yes	Yes	10,940,124
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-001	Aug 18, 2022		RX	Yes	Yes	11,752,144
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-001	Aug 18, 2022		RX	Yes	Yes	10,064,857
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-001	Aug 18, 2022		RX	Yes	Yes	9,370,513
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-001	Aug 18, 2022		RX	Yes	Yes	10,080,727
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-001	Aug 18, 2022		RX	Yes	Yes	11,617,728

International Patents for AUVELITY

When does loss-of-exclusivity occur for AUVELITY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Nicaragua

Peru

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AUVELITY around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	758431	Compositions and methods comprising bupropion or related compounds and dextromethorphan
Mexico	2016005867
Japan	2017535563
Singapore	11201704066V	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION
South Korea	102603013
South Korea	20220161414

Supplementary Protection Certificates for AUVELITY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2316456	65/2017	Austria		PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 (MITTEILUNG) 20150330
2316456	CR 2017 00062	Denmark		PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330
2316456	1790064-8	Sweden		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REG. NO/DATE: EU/1/14/988 20150330
2316456	LUC00054	Luxembourg		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330
0467488	SPC/GB00/019	United Kingdom		PRODUCT NAME: BUPROPION HYDROCHLORIDE; REGISTERED: NL RVG 24160 19991201; UK PL 10949/0340 20000607
2316456	300918	Netherlands		PRODUCT NAME: NALTREXON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER NALTREXONHYDROCHLORIDE, EN BUPROPION OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER BUPROPIONHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150330

Market Dynamics and Financial Trajectory for Auvelity (Aknevity)

Last updated: July 27, 2025

Introduction

Auvelity, marketed as Aknevity in some regions, is a novel pharmaceutical approved for the treatment of major depressive disorder (MDD). Developed by Axsome Therapeutics, Auvelity represents a significant advancement in depression therapy, combining a rapid onset of action with an innovative mechanism of action. Its market potential hinges on an evolving landscape of mental health unmet needs, competitive dynamics, regulatory pathways, and commercialization strategies. This analysis explores the current market environment, key drivers influencing Auvelity’s financial trajectory, and strategic considerations shaping its future.

Market Landscape and Therapeutic Positioning

Depression remains a leading global health challenge, affecting over 300 million individuals worldwide [1]. Despite a broad array of available antidepressants, many patients experience inadequate response, delayed onset, or intolerable side effects, creating substantial unmet needs. Historically, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) dominate prescriptions; however, their limitations foster demand for novel therapies.

Auvelity combines dextromethorphan and bupropion to deliver rapid antidepressant effects, targeting NMDA receptor antagonism and neuroplasticity pathways—mechanisms akin to ketamine but with oral administration and a more established safety profile [2]. The drug’s positioning as a fast-acting, oral therapy expands its appeal among treatment-resistant depression (TRD) populations, particularly those seeking alternatives to intravenous ketamine or esketamine (Spravato).

Competitive Landscape

Auvelity enters a competitive arena comprising legacy antidepressants and emerging rapid-acting agents. Key competitors include:

• Esketamine (Spravato): An FDA-approved nasal spray with proven rapid efficacy but high costs and nasal administration limitations [3].
• Specialized NMDA antagonists: Novel agents in development aim to replicate ketamine’s rapid effects with improved safety.
• Adjunctive therapies: Such as brexanolone, primarily for postpartum depression but expanding to other depressive states.

Auvelity's oral delivery, combined with a familiar safety profile, provides potential advantages over nasal esketamine, which faces logistical challenges and patient adherence issues.

Market Entry Timing and Adoption Drivers

Auvelity’s commercialization began in 2022 in the United States, with subsequent global expansion plans. Given the excruciatingly high prevalence of MDD and treatment-resistant subsets, initial adoption is expected to target:

• TRD patients: Who have failed at least two antidepressant regimens.
• Patients requiring rapid symptom relief: Particularly those experiencing suicidal ideation or severe symptom burden.

Key adoption drivers include:

• Efficacy and speed: Clinical trials demonstrate significant symptom improvement within days.
• Safety profile: Favorability compared to ketamine and esketamine mitigates concerns around dissociation and abuse potential.
• Physician acceptance: Prescribers favor oral, easily integrated treatments that align with existing practices.

Regulatory Considerations and Reimbursement

The FDA’s breakthrough therapy designation for Auvelity accelerated its development and approval process, underscoring its potential to address critical unmet needs [2]. Payer coverage and reimbursement policies will substantially influence market penetration. Early indications suggest favorable reimbursement with existing depression treatment pathways, although formulary positioning remains pivotal.

Financial Trajectory and Growth Projections

Revenue Streams and Market Penetration

Projected revenue growth for Auvelity relies on several variables:

• Market size: The global depression market is substantial. In the US alone, approximately 17 million adults experience MDD annually, with 30-40% classified as treatment-resistant [1].
• Pricing strategy: The initial wholesale acquisition cost (WAC) is estimated around $400 per month, comparable to other branded antidepressants and NMDA antagonists [4].
• Market share assumptions: Given the unmet needs and clinical advantages, Axsome aims for rapid market share gains—targeting 10-20% of the TRD segment within five years.

Sales Forecasts and Revenue Milestones

Early market penetration, supported by key opinion leader endorsements and physician education, suggests:

• Year 1: Estimated US sales between $50-$75 million, primarily driven by initial prescriber adoption.
• Year 3: Potential revenues reaching $200-$400 million as access expands and reimbursement stabilizes.
• Year 5 and beyond: A mature market could generate revenues exceeding $1 billion globally, considering European and Asian approvals.

Cost Structure and Profitability

Development costs managing patent lifecycle, commercialization expenses, and licensing negotiations influence profitability. Given Axsome’s focus on niche indications and high-value prescribing, gross margins are projected above 60%, with profitability contingent on sustained market share.

Market Risks and Challenges

• Competitive pressure: The rapid evolution of depression therapeutics could introduce more efficacious or cost-effective agents.
• Regulatory hurdles: Obtainment of approvals in additional jurisdictions hinges on local clinical data and regulatory timelines.
• Pricing pressures: Payers may negotiate discounts or prefer generics if biosimilar versions emerge, constraining revenue growth.

Strategic Implications for Stakeholders

Investors and healthcare providers should monitor:

• Pipeline developments: Adjunct therapies or expanded indications could enhance Auvelity’s market position.
• Reimbursement landscape: Favorable payer policies will accelerate adoption.
• Market penetration initiatives: Educational campaigns and clinician engagement are vital to accelerate uptake.

Key Takeaways

• Auvelity’s innovative oral formulation and rapid efficacy position it as a transformative agent in MDD treatment, especially among treatment-resistant patients.
• The drug’s commercial success depends on strategic positioning, payer negotiations, and clinical differentiation from existing therapies.
• Revenue projections suggest a rising trajectory, with potential global sales surpassing $1 billion within five years, contingent on market access and uptake.
• Competitive dynamics, regulatory developments, and evolving treatment paradigms remain pivotal risks.
• Stakeholders should prioritize market access efforts, ongoing clinical research, and awareness campaigns to secure long-term growth.

---

FAQs

1. How does Auvelity differ from traditional antidepressants?
Auvelity offers a rapid onset of antidepressant effect, with clinical improvements seen within days, unlike traditional SSRIs/SNRIs that often require weeks. Its unique combination of dextromethorphan and bupropion targets NMDA receptors, providing a novel mechanism of action.

2. What are the primary barriers to Auvelity’s market growth?
Main barriers include clinician familiarity with existing treatments, reimbursement policies, competitive entries like esketamine, and potential safety concerns over off-label use or long-term effects.

3. Can Auvelity expand into indications beyond depression?
While primarily approved for MDD, its mechanism suggests potential in other neuropsychiatric disorders, including bipolar depression or post-viral neuroinflammatory conditions, pending further clinical trials.

4. What is the anticipated long-term market share for Auvelity?
Estimates project that Auvelity could capture 10-20% of the TRD segment within 5 years, with longer-term expansion depending on additional approvals and clinical evidence.

5. How does regulatory approval influence Auvelity’s revenue prospects?
Fast-track and breakthrough designations facilitated quicker access to the market, boosting early revenue streams and solidifying competitive positioning, thereby positively influencing longer-term financial forecasts.

---

References

[1] World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. WHO, 2017.
[2] Axsome Therapeutics. FDA Approves Auvelity (dextromethorphan/bupropion) for Treatment of Major Depressive Disorder. 2022.
[3] U.S. Food and Drug Administration. Esketamine (Spravato). 2019.
[4] Industry analysis reports on depression drug market pricing strategies, 2022.

---

This comprehensive evaluation underscores Auvelity’s promising market dynamics, driven by unmet clinical needs, innovative mechanisms, and strategic regulatory pathways, charting a compelling financial trajectory for stakeholders in the evolving landscape of depression therapeutics.